UK study tracks HAE patients on lanadelumab: fewer attacks expected
NCT ID NCT05469789
First seen Nov 20, 2025 · Last updated May 16, 2026 · Updated 32 times
Summary
This study looks at 50 people in the UK with hereditary angioedema (HAE) who are starting or have started lanadelumab. Researchers will compare the number of swelling attacks in the year before starting the drug to up to two years after. Data comes from medical records, diaries, and phone check-ins every three months. The goal is to see if lanadelumab reduces attacks in everyday practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts Health NHS Trust
London, England, E1 1BB, United Kingdom
Conditions
Explore the condition pages connected to this study.